995-P: Semaglutide in Patients with Type 2 Diabetes: Real-World Analysis in the Canadian LMC Diabetes Registry: The SPARE Study

The Canadian LMC Diabetes Registry will evaluate real-world clinical outcomes in GLP-1 RA naive patients with T2D who initiate once weekly semaglutide as part of their usual diabetes therapy in the first year of semaglutide availability in Canada. Primary outcome is change in A1C at 3 - 6 months follow-up. In this interim retrospective analysis of the first six months of semaglutide availability, 542 patients who initiated semaglutide were eligible (37% on 1.0 mg dose and 63% on 0.5 mg dose). They had a mean age of 57.3 ± 10.1 years, T2D duration of 12.0 ± 7.4 years, and baseline A1C of 8.23 ± 1.34%. At 3-6 months follow-up, 466 patients who remained on-treatment showed an A1C reduction of 0.88 ± 1.15% (p Disclosure R.E. Brown: None. A.R. Liu: Employee; Self; Novo Nordisk A/S. R. Mahbubani: Employee; Self; Novo Nordisk Inc. R. Aronson: Research Support; Self; AstraZeneca, Becton, Dickinson and Company, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Medtronic, Merck & Co., Inc., Novo Nordisk Inc., Sanofi, Senseonics. Funding Novo Nordisk Canada Inc.